穆殿平 刘新 (天津市第一中心医院药剂科 天津 300192)
摘 要 目的：建立测定卡马西平（CBZ）的高效液相色谱法，分析CBZ在健康受试者体内药动学特性，探讨临床应用个体差异的原因。方法：12名健康受试者单剂量（200 mg）口服CBZ片，HPLC法测定血浆样品药物浓度。结果：CBZ的线性范围为（0.05～10）μg•ml-1，最低检测浓度为0.05 μg•ml-1，方法平均回收率为94.4%。单剂量口服CBZ后血浆浓度符合一级吸收一房室模型,其主要药动学参数为：Cmax为(4.71±0.99)μg•ml-1，tmax为(16±12)h，AUC为(361.62±49.43)μg•h•ml-1，t1/2=(38.39±6.37)h。结论：该法测定血浆中CBZ浓度高效、灵敏、准确，CBZ体内药动学特性存在明显个体差异。
关键词 卡马西平；药物动力学；高效液相色谱法
中图分类号：R969.3
文献标识码：A
文章编号：1008-049X(2007)10-0960-03
Pharmacokinetics Profile of Carbamazepine Tablets in Healthy Volunteers
Mu Dianping, Liu Xin(Pharmacy Department, First Central Hospital of Tianjin City, Tianjin 300192, China)
ABSTRACT Objective: To establish an HPLC method for the determination of carbamazepine concentration in human plasma and explore the reason of individual variation of this drug through analyzing its pharmacokinetics profile in Chinese healthy volunteers．Method: A single 200 mg dose of carbamazepine was performed in healthy male volunteers．Plasma drug concentration was determined by HPLC.Result: The linear range of CBZ was 0.05～10 μg•ml-1,the quantitative limit was 0.05 μg•ml-1which was enough to detect the concentration of CBZ in plasma, the average recovery was 94.4%,the main pharmacokinetics parameters were (4.71±0.99)μg•ml-1 for Cmax,(16±12)h for tmax,(361.62±49.43)μg•h•ml-1for AUC,(38.39±6.37)h fort1/2, respectively.Plasmadrug concentration curve of CBZ in single oral administration was conformed to be one compartment model of the first order absorption.Conclusion: The method was high sensitivity and selectivity for determination the plasma-drug concentration of CBZ in human. The pharmacokinetics profile proved to be significant individual difference of this drug.
KEY WORDS Carbamazepine；Pharmacokinetics；HPLC
参 考 文 献
1 唐荣福，张莉.卡马西平血药浓度与抗癫痫作用及不良反应的关系［J］.中国新药杂志，2003，12（10）：865-866
2 胡敏燕，郑萍，刘世震，等．得理多与两种国产卡马西平在人体内生物利用度研究［J］．中国医院药学杂志, 1998,18（10）:435-438
3 赵香兰，王建华．血清及唾液卡马西平代谢动力学研究比较［J］．中国神经精神疾病杂志, 1990,16（3）：156-158
4 Bourgeois BFD. Pharmacokinetic properties of current antiepileptic drugs: What improvements are needed?［J］.Neurology,2000,55:S11-S16
5 钟明康，张静华，王宏图，等．卡马西平的药物动力学特性［J］．中国医院药学杂志, 1995,15（1）：24-25
6 Alexishvili MM, Rukhadze MD, Okujava VM. Simultaneous determination of carbamazepine and carbamazepine 10,11菌素epoxide by using microcolumn HPLC: Study of pharmacokinetics of carbamazepine in a volunteer［J］.BiomedChromatogr, 1997, 11(1):36-41
7 郑萍，胡敏燕，刘世霆，等.浅析卡马西平血药浓度的多峰现象［J］．中国药房, 1999,10(1)：45
8 Winnicka RI, Fopacinski B, Szymczak WM,et al.Carbamazepine poisoning: Elimination kinetics and quantitative relationship with carbamazepine 10,11epoxide［J］.Clinical toxicology,2002,40(6):759-765
9 孙步生，张琴芳．癫痫患者体内卡马西平浓度的比较研究［J］．医药导报, 1996,15（3）：104-105
10 Kulkarni C, Vsz J, David J, et al. Ammophylline alters pharmacokinetics of carbamazepine but not that of sodium valproatea single dose pharmacokinetic study in human volunteers［J］.IndianJPhysiolPharmacol,1995,39(2):122-126 资料来自:中国药师-专业站 |